Heart inflammation and scarring in Fabry disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study uses advanced heart scans (PET/CT and MRI) to look at inflammation, blood vessel health, and scarring in the hearts of people with Fabry disease. It aims to better understand how Fabry disease affects the heart and find new ways to track or treat these changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Fabry disease through genetic testing.
- You are 18 years or older.
- You can understand and agree to take part in the study (give informed consent).
- You cannot have certain conditions that make heart imaging unsafe, such as recent heart attack, severe asthma, or certain heart rhythm problems.
- You cannot have metal implants, devices, or tattoos that are not safe for MRI scans, or severe claustrophobia.
- You must not be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses MRI scans to look at how Fabry disease affects the kidneys, including scarring, swelling, and oxygen levels. It may help researchers understand kidney problems better and find new ways to monitor the disease.
This study looks at early structural and tissue changes in the heart using a special type of MRI scan in adults with Fabry disease. It may help doctors understand changes earlier and better track heart involvement over time.
This study looks at new ways to detect and predict heart problems in people with Fabry disease. By participating, you may help improve early diagnosis and care for this condition.
This study uses heart MRI to look at a specific heart tissue change in women with Fabry disease who have not yet started treatment. It aims to understand if this change could help guide future treatment decisions.
This study looks at how the heart is affected in adults with Fabry disease. It may help doctors better understand heart-related changes in order to guide care.
This study is for people with Fabry disease who are taking or planning to take the medication Elfabrio (pegunigalsidase alfa). It will look at how safe and effective the treatment is in real-world use.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.